VIRGINIA RETIREMENT SYSTEMS ET Al Takes $5.21 Million Position in Elanco Animal Health Incorporated $ELAN

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Elanco Animal Health Incorporated (NYSE:ELAN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 211,873 shares of the company’s stock, valued at approximately $5,214,000.

A number of other institutional investors and hedge funds have also modified their holdings of ELAN. BlackRock Inc. acquired a new position in shares of Elanco Animal Health in the 2nd quarter valued at about $1,202,198,000. Peak Retirement Planning Inc. acquired a new stake in shares of Elanco Animal Health during the fourth quarter worth approximately $2,756,000. Norges Bank acquired a new stake in shares of Elanco Animal Health during the fourth quarter worth approximately $32,415,000. S&CO Inc. purchased a new position in Elanco Animal Health during the second quarter valued at approximately $2,738,000. Finally, Geneos Wealth Management Inc. increased its stake in Elanco Animal Health by 3,358.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 202,747 shares of the company’s stock valued at $4,852,000 after buying an additional 196,884 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Down 2.3%

ELAN stock opened at $23.95 on Wednesday. The firm has a market cap of $11.96 billion, a PE ratio of -58.41, a PEG ratio of 1.83 and a beta of 1.68. Elanco Animal Health Incorporated has a 1 year low of $18.22 and a 1 year high of $27.98. The company has a fifty day simple moving average of $24.63 and a 200 day simple moving average of $23.96. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. During the same period in the prior year, the business posted $0.26 earnings per share. The business’s quarterly revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Sell-side analysts anticipate that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In related news, insider Shiv O’Neill bought 3,998 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, August 18th. The stock was purchased at an average cost of $23.58 per share, for a total transaction of $94,272.84. Following the acquisition, the insider owned 87,832 shares in the company, valued at $2,071,078.56. This trade represents a 4.77% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Paul Herendeen bought 10,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were bought at an average cost of $23.68 per share, with a total value of $236,800.00. Following the transaction, the director directly owned 111,687 shares of the company’s stock, valued at approximately $2,644,748.16. This trade represents a 9.83% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 63,198 shares of company stock worth $1,473,109 in the last 90 days. Company insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ELAN shares. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday. KeyCorp lifted their price objective on Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. TD Cowen boosted their target price on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Finally, Morgan Stanley upped their target price on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.